Ítem
Acceso Abierto

Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease

Mostrar el registro sencillo de la publicación
dc.creatorJoura, Elmar A.spa
dc.creatorAult, Kevin Aspa
dc.creatorBosch, F Xavierspa
dc.creatorBrown, Darronspa
dc.creatorCuzick, Jackspa
dc.creatorFerris, Daronspa
dc.creatorGarland, Suzanne M.spa
dc.creatorGiuliano, Anna Rspa
dc.creatorHernandez-Avila, Mauriciospa
dc.creatorHuh, Warnerspa
dc.creatorIversen, Ole-Erikspa
dc.creatorKjaer, Susanne Kspa
dc.creatorLuna, Joaquinspa
dc.creatorMiller, Diannespa
dc.creatorMonsonego, Josephspa
dc.creatorMunoz, Nubiaspa
dc.creatorMyers, Evanspa
dc.creatorPaavonen, Jormaspa
dc.creatorPitisuttithum, Punneespa
dc.creatorSteben, Marcspa
dc.creatorWheeler, Cosette Mspa
dc.creatorPerez, Gonzalospa
dc.creatorSaah, Alfredspa
dc.creatorLuxembourg, Alainspa
dc.creatorSings, Heather Lspa
dc.creatorVelicer, Christinespa
dc.date.accessioned2020-05-26T00:03:50Z
dc.date.available2020-05-26T00:03:50Z
dc.date.created2014spa
dc.description.abstractBackground: We estimated the prevalence and incidence of 14 human papillomavirus (HPV) types (6/11/ 16/18/31/33/35/39/45/51/52/56/58/59) in cervicovaginal swabs, and the attribution of these HPV types in cervical intraepithelial neoplasia (CIN), and adenocarcinoma in situ (AIS), using predefined algorithms that adjusted for multiple-type infected lesions. Methods: A total of 10,656 women ages 15 to 26 years and 1,858 women ages 24 to 45 years were enrolled in the placebo arms of one of three clinical trials of a quadrivalent HPV vaccine. We estimated the cumulative incidence of persistent infection and the proportion of CIN/AIS attributable to individual carcinogenic HPV genotypes, as well as the proportion of CIN/AIS lesions potentially preventable by a prophylactic 9-valent HPV6/11/16/18/31/33/45/52/58 vaccine. Results: The cumulative incidence of persistent infection with?1 of the seven high-risk types included in the 9-valent vaccine was 29%, 12%, and6%forwomen ages 15 to 26, 24 to 34, and 35 to 45 years, respectively.Atotal of 2,507 lesions were diagnosed as CIN or AIS by an expert pathology panel. After adjusting for multiple-type infected lesions, amongwomen ages 15 to 45 years, these seven high-risk types were attributed to 43% to 55% of CIN1, 70% to 78% of CIN2, 85% to 91% of CIN3, and 95% to 100% of AIS lesions, respectively. The other tested types (HPV35/39/51/56/59) were attributed to 23% to 30% of CIN1, 7% to 14% of CIN2, 3% to 4% of CIN3, and 0% of AIS lesions, respectively. Conclusions: Approximately 85% or more of CIN3/AIS, >70% CIN2, and approximately 50% of CIN1 lesions worldwide are attributed to HPV6/11/16/18/31/33/45/52/58. Impact: If 9-valent HPV vaccination programs are effectively implemented, the majority of CIN2 and CIN3 lesions worldwide could be prevented, in addition to approximately one-half of CIN1.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1158/1055-9965.EPI-14-0410
dc.identifier.issn10559965
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/23633
dc.language.isoengspa
dc.publisherAmerican Association for Cancer Research Inc.spa
dc.relation.citationEndPage2008
dc.relation.citationIssueNo. 10
dc.relation.citationStartPage1997
dc.relation.citationTitleCancer Epidemiology Biomarkers and Prevention
dc.relation.citationVolumeVol. 23
dc.relation.ispartofCancer Epidemiology Biomarkers and Prevention, ISSN:10559965, Vol.23, No.10 (2014); pp. 1997-2008spa
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84907516546&doi=10.1158%2f1055-9965.EPI-14-0410&partnerID=40&md5=44abfdae5f9caa3386b7d2f3da9c9b90spa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordPlacebospa
dc.subject.keywordWart virus vaccinespa
dc.subject.keywordWart virus vaccinespa
dc.subject.keywordAdenocarcinomaspa
dc.subject.keywordAdolescentspa
dc.subject.keywordAdultspa
dc.subject.keywordAlgorithmspa
dc.subject.keywordAlphapapillomavirusspa
dc.subject.keywordArticlespa
dc.subject.keywordControlled studyspa
dc.subject.keywordDouble blind procedurespa
dc.subject.keywordDrug efficacyspa
dc.subject.keywordDrug safetyspa
dc.subject.keywordFemalespa
dc.subject.keywordFollow upspa
dc.subject.keywordGenotypespa
dc.subject.keywordGroups by agespa
dc.subject.keywordHigh risk patientspa
dc.subject.keywordHumanspa
dc.subject.keywordHuman papillomavirus type 11spa
dc.subject.keywordHuman papillomavirus type 16spa
dc.subject.keywordHuman papillomavirus type 18spa
dc.subject.keywordHuman papillomavirus type 31spa
dc.subject.keywordHuman papillomavirus type 33spa
dc.subject.keywordHuman papillomavirus type 35spa
dc.subject.keywordHuman papillomavirus type 39spa
dc.subject.keywordHuman papillomavirus type 45spa
dc.subject.keywordHuman papillomavirus type 51spa
dc.subject.keywordHuman papillomavirus type 52spa
dc.subject.keywordHuman papillomavirus type 56spa
dc.subject.keywordHuman papillomavirus type 58spa
dc.subject.keywordHuman papillomavirus type 59spa
dc.subject.keywordHuman papillomavirus type 6spa
dc.subject.keywordHuman tissuespa
dc.subject.keywordIncidencespa
dc.subject.keywordInfection preventionspa
dc.subject.keywordMajor clinical studyspa
dc.subject.keywordMixed infectionspa
dc.subject.keywordNonhumanspa
dc.subject.keywordPapanicolaou testspa
dc.subject.keywordPapillomavirus infectionspa
dc.subject.keywordPersistent infectionspa
dc.subject.keywordPhase 3 clinical trialspa
dc.subject.keywordPrevalencespa
dc.subject.keywordRandomized controlled trialspa
dc.subject.keywordUterine cervix adenocarcinomaspa
dc.subject.keywordUterine cervix biopsyspa
dc.subject.keywordUterine cervix cancerspa
dc.subject.keywordUterine cervix carcinoma in situspa
dc.subject.keywordUterine cervix cytologyspa
dc.subject.keywordVaccinationspa
dc.subject.keywordCervical intraepithelial neoplasiaspa
dc.subject.keywordGeneticsspa
dc.subject.keywordGenotypespa
dc.subject.keywordMiddle agedspa
dc.subject.keywordPapillomaviridaespa
dc.subject.keywordPapillomavirus infectionsspa
dc.subject.keywordRisk factorspa
dc.subject.keywordUterine cervical neoplasmsspa
dc.subject.keywordVirologyspa
dc.subject.keywordYoung adultspa
dc.subject.keywordAdolescentspa
dc.subject.keywordAdultspa
dc.subject.keywordCervical intraepithelial neoplasiaspa
dc.subject.keywordDouble-blind methodspa
dc.subject.keywordFemalespa
dc.subject.keywordGenotypespa
dc.subject.keywordHumansspa
dc.subject.keywordIncidencespa
dc.subject.keywordMiddle agedspa
dc.subject.keywordPapillomaviridaespa
dc.subject.keywordPapillomavirus infectionsspa
dc.subject.keywordPapillomavirus vaccinesspa
dc.subject.keywordPrevalencespa
dc.subject.keywordRisk factorsspa
dc.subject.keywordUterine cervical neoplasmsspa
dc.subject.keywordYoung adultspa
dc.titleAttribution of 12 high-risk human papillomavirus genotypes to infection and cervical diseasespa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Bloque original
Mostrando1 - 1 de 1
Miniatura
Nombre:
1997-full.pdf
Tamaño:
1.31 MB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Colecciones
Artículos